BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12134707)

  • 41. [Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide].
    Kikuta T; Shimazaki C; Hirai H; Sumikuma T; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Fujita N; Hatta T; Nakagawa M
    Rinsho Ketsueki; 1996 Nov; 37(11):1276-82. PubMed ID: 8960661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
    Miyazaki E; Takemoto Y; Kanamaru A; Kakishita E; Nagai K; Masaoka T; Shibata H; Horiuti A; Tsubaki K; Yonezawa T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):497-503. PubMed ID: 1558399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
    Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [DBMP-85 was effective at diagnosis and LVP was effective at relapse in a case of acute mixed leukemia].
    Endo M; Kanemaru M; Kubo Y; Kouda K; Sakurai T; Iizuka Y; Takeuchi J; Horikoshi A; Ohshima T
    Rinsho Ketsueki; 1990 Mar; 31(3):320-4. PubMed ID: 2366335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Complete remission induced by combined treatment with all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) in a patient with relapsed acute promyelocytic leukemia].
    Wakayama T; Furuya H; Takagi C; Ichiba S; Kato Y
    Rinsho Ketsueki; 1994 Nov; 35(11):1315-21. PubMed ID: 7529843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
    Zhang X; Li Y; Zhang Y; Chen X; Zhang C; Gao L; Kong P; Liu Y; Wen Q; Zeng Y; Wang Q; Su Y; Wang C; Wang S; Yuan Z; Gao L
    Leuk Res; 2013 Jun; 37(6):657-64. PubMed ID: 23537708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
    Zwick C; Birkmann J; Peter N; Bodenstein H; Fuchs R; Hänel M; Reiser M; Hensel M; Clemens M; Zeynalova S; Ziepert M; Pfreundschuh M;
    Ann Hematol; 2008 Sep; 87(9):717-26. PubMed ID: 18587579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
    Orlandi E; Lazzarino M; Bernasconi P; Astori C; Bernasconi C
    Haematologica; 1998 Aug; 83(8):758-9. PubMed ID: 9793267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement].
    Tomita N; Fujita H; Koharazawa H; Maruta A; Kodama F; Yamamoto T; Kobayashi S; Okubo T
    Rinsho Ketsueki; 1997 Feb; 38(2):135-41. PubMed ID: 9059068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
    Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
    Todeschini G; Tecchio C; Pasini F; Benedetti F; Cantini M; Crippa C; Draisci M; Pizzolo G
    Cancer; 2005 Aug; 104(3):555-60. PubMed ID: 15959910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
    Qiu HY; Wu DP; Sun AN; Chang WR; Jin ZM; Miao M; Tang XW; Shen YM; Fu ZZ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):462-5. PubMed ID: 15555260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapy-related acute myeloid leukemia following double autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma].
    Fujii H; Iwai T; Ueda Y; Nakagawa H
    Rinsho Ketsueki; 2002 Jun; 43(6):482-7. PubMed ID: 12134706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.